Gleevec News and Research

RSS
Gleevec is a drug used to treat different types of leukemia and other cancers of the blood, gastrointestinal stromal tumors, skin tumors called dermatofibrosarcoma protuberans, and a rare condition called systemic mastocytosis. It is also being studied in the treatment of other types of cancer. Gleevec blocks the protein made by the bcr/abl oncogene. It is a type of tyrosine kinase inhibitor. Also called imatinib mesylate and STI571.
Researchers identify new gene fusions and mutations linked to subset of GIST patients

Researchers identify new gene fusions and mutations linked to subset of GIST patients

High out-of-pocket costs may delay Medicare patients' access to novel targeted treatment for cancer

High out-of-pocket costs may delay Medicare patients' access to novel targeted treatment for cancer

EPFL scientists develop new method to cheaply produce chemical compounds

EPFL scientists develop new method to cheaply produce chemical compounds

Kataegis linked to better prognosis for breast cancer patients

Kataegis linked to better prognosis for breast cancer patients

Researchers examine critical role of hypoxia in induction, amplification of FOP lesions

Researchers examine critical role of hypoxia in induction, amplification of FOP lesions

New oral cancer drugs getting more expensive over time, study shows

New oral cancer drugs getting more expensive over time, study shows

Gleevec could be novel therapeutic agent for type 2 diabetes

Gleevec could be novel therapeutic agent for type 2 diabetes

Set of genes identified in human genome essential for survival, proliferation of human cell lines

Set of genes identified in human genome essential for survival, proliferation of human cell lines

UCLA's Jonsson Comprehensive Cancer Center named among top 10 cancer centers in nation

UCLA's Jonsson Comprehensive Cancer Center named among top 10 cancer centers in nation

Novartis to highlight strength of its expanded oncology portfolio at ASCO 2015

Novartis to highlight strength of its expanded oncology portfolio at ASCO 2015

Low doses of imatinib drug can push immune system to combat bacterial infections

Low doses of imatinib drug can push immune system to combat bacterial infections

New study finds increase in use of adjuvant systemic therapy for gastrointestinal stromal tumors

New study finds increase in use of adjuvant systemic therapy for gastrointestinal stromal tumors

Evolution of two protein kinases may hold key to unlocking highly specific cancer drugs

Evolution of two protein kinases may hold key to unlocking highly specific cancer drugs

Franziska Michor named winner of Creative Promise Prize in Biomedical Science

Franziska Michor named winner of Creative Promise Prize in Biomedical Science

Drug similar to Gleevec may help tame some brain cancers

Drug similar to Gleevec may help tame some brain cancers

Yale researcher receives 2015 Frontiers of Knowledge Award in Biomedicine

Yale researcher receives 2015 Frontiers of Knowledge Award in Biomedicine

Novartis to highlight advances in blood, breast cancer research at ASH and SABCS 2014

Novartis to highlight advances in blood, breast cancer research at ASH and SABCS 2014

Aptose joins Beat AML research collaboration

Aptose joins Beat AML research collaboration

Study reveals how BTK mutation triggers drug resistance in CLL patients

Study reveals how BTK mutation triggers drug resistance in CLL patients

First Edition: May 16, 2014

First Edition: May 16, 2014